Samsung Epis Holdings was established with a vision to improve human health and help people live healthier lives by pursuing continuous innovations in biotechnology. Building on our research capabilities and pioneering spirit in biopharmaceuticals, we are shaping the future of the global biopharmaceutical market.

Through our subsidiary Samsung Bioepis, we are expanding access to biologic medicines, by allowing more patients to benefit from high-quality biosimilar medicines at affordable costs. Driven by an unwavering commitment to quality and world-class technological expertise, we have enhanced the quality of life for patients around the world.

However, we will not stop here. We are ready to open up a new horizon of biopharmaceutical innovations through strategic management of the biosimilar business, while proactively investing in next-generation biotechnologies through Samsung Epis Holdings. Our continued innovations and investments in future biotechnologies will enable us to address unmet medical needs and develop new therapies that will help treat many chronic and life-threatening diseases.

Samsung Epis Holdings will continue to make inroads as a pioneer, writing a new history in the biopharmaceutical market without ceasing to challenge ourselves. We ask for your continued trust and support on this journey.

Samsung Epis Holdings
Kyung-Ah Kim President & CEO